Comscore Partners with STRONG Technical Services for Theatre Device Monitoring

Integration enables seamless management of theatrical hardware and content

PR Newswire

RESTON, Va., Nov. 16, 2020 /PRNewswire/ — Comscore (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today announced a partnership with Ballantyne Strong, Inc.’s (NYSE American: BTN) subsidiary STRONG Technical Services, a leader in projection equipment sales, engineering, and services, for enhanced detailed device monitoring in Comscore’s Enterprise Web™.

Subscribers of Enterprise Web will be able to review projection hardware status circuit-wide, enabling them to centrally monitor and manage media players and projectors, and key delivery and playout reporting as well as content and other hardware from one integrated application in near real-time. The partnership also allows Strong’s Management System subscribers to title map features and build preshow content packs using Enterprise Web’s functionality. This capability fills a crucial gap for theatrical exhibitors, streamlining operations into one integrated online interface.

“We are thrilled to partner with Strong Technical Services to add device monitoring capabilities to Enterprise Web,” said Arturo Guillén, Executive Vice President and Global Managing Director, Comscore Movies. “This integration brings their hardware monitoring and our content management capabilities together, creating an efficient, circuit-wide theater management experience.”

“Partnering with Comscore to deliver hardware monitoring for Enterprise Web was a natural progression in our service delivery development,” said Blake Titman, Vice President and General Manager, STRONG Technical Services. “STRONG has worked with the Comscore team for many years to support Comscore’s Theatre Management System (TMS). The partnership allows us to deliver on our goal of allowing exhibitors to manage their sight and sound operations with a single interface.”

Comscore Enterprise Web gives circuit managers an over-the-shoulder look at operations inside all of their theatres from one centralized website. A secure web-based application, it allows a single staff member to centrally title map features, manage keys (KDMs) and create trailer packs across all theatres, in turn, creating circuit-wide efficiencies, while also alerting users to any issues that could prevent shows from playing out as scheduled.

About Comscore
Comscore (NASDAQ: SCOR) is a trusted partner for planning, transacting and evaluating media across platforms. With a data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore allows media buyers and sellers to quantify their multiscreen behavior and make business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry’s emerging, third-party source for reliable and comprehensive cross-platform measurement. To learn more, visit www.comscore.com.

About STRONG Technical Services
STRONG Technical Services, Inc. (www.strong-tech.com), a Ballantyne Strong, Inc. company, is an equipment sales, engineering, and service provider located in Omaha, NE. The company, with its nationwide service and engineering team, designs, integrates, and installs technology solutions for a broad range of applications including audio, projection, and signage applications with comprehensive managed service offerings to ensure solution uptime and availability.

About Ballantyne Strong, Inc.

Ballantyne Strong, Inc. (NYSE American: BTN)  (www.ballantynestrong.com) and its subsidiaries engage in diverse business activities including the design, integration and installation of technology solutions for a broad range of applications; development and delivery of out-of-home messaging, advertising and communications; manufacturing of projection screens; and providing managed services including monitoring of networked equipment. The Company focuses on serving the entertainment, retail and advertising markets.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/comscore-partners-with-strong-technical-services-for-theatre-device-monitoring-301173165.html

SOURCE Comscore

SM Energy Announces Reaffirmation of Borrowing Base and Agreement for South Texas Well Completions

PR Newswire

DENVER, Nov. 16, 2020 /PRNewswire/ — SM Energy Company (the “Company”) (NYSE: SM) provides a fourth quarter 2020 update. The Company and its lenders under the senior secured revolving credit facility have completed the regularly scheduled fall borrowing base redetermination, and the Company has entered into an agreement with a third party to partly fund South Texas well completions.

The borrowing base and lender commitments under the Company’s senior secured revolving credit facility were reaffirmed at $1.1 billion, which provided liquidity of approximately $880 million as of September 30, 2020. In addition, the Company’s second-lien debt capacity of approximately $380 million was extended until the spring 2021 borrowing base redetermination.

The Company also announced that it has entered into an agreement with a third party to fund the majority of completion costs associated with six wells in South Texas. As a result, fourth quarter capital expenditure guidance is reduced by approximately $15 million. The well completion program associated with the agreement includes co-development of three lower Eagle Ford and three Austin Chalk wells currently in the Company’s DUC inventory. The Company will operate the wells and retain a 50% working interest.

As previously announced, an updated investor presentation will be posted to the Company’s website before market open on November 18, 2020.

FORWARD LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release that address events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Statements concerning future expectations or projections, or similar expressions, are intended to identify forward-looking statements. Such forward-looking statements are based on assumptions and analyses made by SM Energy in light of its perception of current conditions, expected future developments, and other factors that SM Energy believes are appropriate under the circumstances. These statements are subject to a number of known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future performance and actual events may be materially different from those expressed or implied in the forward-looking statements. The forward-looking statements in this press release speak as of the date of this press release.

ABOUT THE COMPANY

SM Energy Company is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and NGLs in the state of Texas.  SM Energy routinely posts important information about the Company on its website. For more information about SM Energy, please visit its website at www.sm-energy.com.

SM ENERGY INVESTOR CONTACT 

Jennifer Martin Samuels, [email protected], 303-864-2507

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sm-energy-announces-reaffirmation-of-borrowing-base-and-agreement-for-south-texas-well-completions-301173302.html

SOURCE SM Energy Company

Liberty Global Announces Executive Leadership in Switzerland

Liberty Global Announces Executive Leadership in Switzerland

André Krause Named CEO of Combined Sunrise UPC Business

Severina Pascu Returning to Switzerland to Serve as Deputy CEO and COO

DENVER, Colorado–(BUSINESS WIRE)–
Liberty Global (Nasdaq: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, today announced the appointment of two senior executives to lead its newly combined Swiss operations following the closing of its acquisition of Sunrise Communications AG (SIX Swiss Exchange: SRCG) last week.

Effective immediately, André Krause is Chief Executive Officer of the combined Sunrise UPC business. He joins Liberty Global’s executive team, reporting to CEO Mike Fries. Krause is currently the CEO of Sunrise and served as the mobile operator’s Chief Financial Officer (CFO) for eight years prior. He was critical in leading the transformation of Sunrise’s network, customer service, brand and company culture and instrumental in the successful IPO and listing of the company on the Swiss exchange in 2015.

Additionally, Severina Pascu will return to Switzerland to serve as Deputy CEO and Chief Operating Officer (COO), reporting to Krause. Pascu has been a longtime member of the Liberty Global family, having served most recently as CFO and Deputy CEO of Virgin Media in the United Kingdom. Prior to that she was CEO of UPC Switzerland from September of 2018 to January of 2020, and has spent the last 10 years in leadership positions in Liberty Global’s Central and Eastern European operations. Pascu will lead the combined consumer and business organizations, operations and digital functions.

“This is an exciting time in Switzerland as we bring these two major brands together for the benefit of consumers, businesses and employees,” said Fries. “André is an outstanding executive with a proven track record of growth, innovation and value creation at Sunrise. He is uniquely qualified to lead the integration of these two businesses and deliver on our long-term strategic growth plans in the market. He will also be a great addition to my senior leadership team where his mobile experience will be particularly valuable, and he can benefit from our success in other fixed-mobile markets.”

“I am also thrilled to have Severina back in Switzerland,” Fries added. “She is a world class operator with deep experience in the Swiss market and clear understanding of what it takes to build a converged national champion. She and André are a “dream team” that will provide leadership, continuity and strategic clarity to Sunrise UPC at this critical juncture.”

“By combining UPC’s leading gigabit broadband network and the leading 5G mobile network of Sunrise, we are creating the best connectivity platform for Swiss consumers and businesses for the future,” said Krause. “With Liberty Global’s proven expertise for creating leading fixed-mobile champions across Europe we will set new standards in the Swiss market in the coming years. I am excited and honored to shape this next chapter of the combined Sunrise UPC business together with extraordinary people as one team.”

Pascu added, “I strongly believe that this combined Sunrise UPC business will make a difference in the Swiss market and will create significant benefits for consumers and businesses across Switzerland. Together with our employees we have a unique opportunity to build the future of Switzerland. I am very much looking forward to this new role and being part of this journey together with André, the leadership team and all our employees to become the national converged champion.”

Baptiest Coopmans, who has served as CEO of UPC Switzerland for the last 10 months, will return to a senior operating role at Liberty Global. Fries said, “Baptiest did a fantastic job in his short tenure at UPC. In a difficult year, he accelerated commercial momentum, simplified the operating structure and energized the team.”

ABOUT LIBERTY GLOBAL

Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in 6 European countries under the consumer brands Virgin Media, Telenet and UPC. We invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.

Our substantial scale and commitment to innovation enable us to develop market-leading products delivered through next-generation networks that connect 11 million customers subscribing to 25 million TV, broadband internet and telephony services. We also serve 6 million mobile subscribers and offer WiFi service through millions of access points across our footprint.

In addition, Liberty Global owns 50% of VodafoneZiggo, a joint venture in the Netherlands with 4 million customers subscribing to 10 million fixed-line and 5 million mobile services, as well as significant investments in ITV, All3Media, ITI Neovision, LionsGate, the Formula E racing series and several regional sports networks.

For more information, please visit www.libertyglobal.com.

Investor Relations:

Max Adkins +44 20 8483 6336

John Rea +1 303 220 4238

Stefan Halters +44 20 8483 6211

Corporate Communications:

Molly Bruce +1 303 220 4202

Matt Beake +44 20 8483 6428

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Technology Telecommunications

MEDIA:

Diamond S Shipping Inc. Reports Third Quarter 2020 Results

Diamond S Shipping Inc. Reports Third Quarter 2020 Results

GREENWICH, Conn.–(BUSINESS WIRE)–
Diamond S Shipping Inc. (NYSE: DSSI) (“Diamond S”, or the “Company”), one of the largest publicly listed owners and operators of crude oil and product tankers, today announced results for the third quarter of 2020.

Highlights for the Third Quarter and Recent Events

— Reported net loss attributable to Diamond S of $9.7 million, or net loss of $0.24 basic and diluted earnings per share, and Adjusted EBITDA (see Non-GAAP Measures section below) of $27.1 million.

— Net debt at September 30, 2020 was $611.1 million, implying a net debt to asset value leverage ratio of 39% based on broker valuations as of June 2020. At quarter end, total free liquidity available to the Company above bank minimum cash requirements was $124.3 million.

— Agreed to sell a 2009-built MR vessel, the Atlantic Mirage, which is expected to be delivered to the buyers in late Q4 2020. The sale of the vessel is expected to generate approximately $7 million in net proceeds before settlement of working capital.

Craig H. Stevenson Jr., President and CEO of Diamond S, commented: “In these challenging market conditions, we are focused on maintaining safe operations and generating the highest possible cash flow in the spot market. To that end, we are pleased with the performance of our new commercial manager, the Norient Product Pool, who absorbed 28 of our MR vessels during the third quarter and outperformed industry benchmarks. Another priority in this environment is ensuring liquidity and maintaining the strong position of our balance sheet. Our recent agreement to sell one of our MR vessels reinforces our view of the underlying value of our enterprise. We are selling a 2009-built MR tanker for $16.4 million. This asset sale is a tangible marker of the value of our fleet, which is well in excess of our current market capitalization. We will continue to prove out the inherent value of DSSI and, especially given the positive long term outlook for our market, we expect to see the disconnect between our intrinsic value and our share price diminish.”

Third Quarter 2020 Results

Reported net loss attributable to Diamond S for the third quarter of 2020 was $9.7 million, or net loss of $0.24 basic and diluted earnings per share, compared to a net loss of $25.9 million, or $0.65 per basic and diluted share, for the third quarter of 2019, which included the impact of a loss on vessel sales of $18.3 million, or $0.46 per share. The decrease in net income for the third quarter of 2020 compared to the adjusted net income for the third quarter of 2019 is primarily related to weaker tanker market conditions.

The Company groups its business primarily by commodity transported and segments its fleet into a 16-vessel crude oil transportation fleet (the “Crude Fleet”) and a 50-vessel refined petroleum product transportation fleet (the “Product Fleet”). The Crude Fleet consists of 15 Suezmax vessels and one Aframax vessel. The Product Fleet consists of 44 medium range (“MR2”) vessels and 6 Handysize (“MR1”) vessels.

Net revenues for the Company, which represents voyage revenues less voyage expenses, were $79.7 million for the third quarter of 2020 compared to $81.6 million for the third quarter of 2019. Net revenues from the Crude Fleet were $29.4 million in the third quarter of 2020 compared to $23.3 million for the third quarter of 2019. The increase in net revenues for the Crude Fleet were primarily due to a solid start to the quarter as a result of the carryover of strong rates from the first half of 2020. Net revenues from the Product Fleet were $50.3 million in the third quarter of 2020 compared to $58.3 million for the third quarter of 2019. The decrease in net revenues in the Product Fleet was principally driven by weaker market conditions. The weak market conditions were driven by demand destruction caused by the global pandemic, and the unwinding of the floating storage cycle, which effectively increased the supply of available ships.

Vessel expenses were $44.8 million for the third quarter of 2020 compared to $41.8 million for the third quarter of 2019. Vessel expenses, which include crew costs, insurance, repairs and maintenance, lubricants and spare parts, technical management fees and other miscellaneous expenses, increased by $3.0 million primarily due to additional expenses incurred for crew bonuses, increased costs of crew reliefs, testing, quarantine and logistics for delivery of services and materials to the vessels as a result of the global pandemic.

Depreciation and amortization expense was $29.1 million in the third quarter of 2020 compared to $28.8 million for the third quarter of 2019.

General and administrative expenses were $7.7 million in the third quarter of 2020 compared to $7.6 million for the third quarter of 2019.

Interest expense was $7.0 million in the third quarter of 2020 compared to $13.0 million for the third quarter of 2019. Interest expense decreased in the third quarter of 2020 due to a lower average debt balance as a result of debt repayments and a decrease in the effective interest rate. Total gross debt outstanding as of September 30, 2020 was $748.5 million, or 16% lower compared to September 30, 2019.

Other income, which consists primarily of interest income, was less than $0.1 million in the third quarter of 2020, compared to $0.5 million for the third quarter of 2019.

Liquidity

As of September 30, 2020, the Company had $120.3 million in cash and restricted cash and $60.0 million available under its revolving credit facility. Available liquidity as of September 30, 2020 was $124.3 million, net of $56.0 million in restricted cash and minimum cash required by debt covenants.

Outlook

Tanker market conditions are expected to remain under pressure during the fourth quarter of 2020, driven by weak demand for crude oil and refined products as a result of the global pandemic. The typical seasonal market strength is expected to be muted as oil inventories continue to draw from onshore storage and demand has not materially recovered. Tanker supply remains balanced based on pre-pandemic demand levels, and the number of vessels on order nearly matches the number of vessels that might be expected to be scrapped, based on the average useful life of a vessel.

As of November 12, 2020, approximately 58% of Crude Fleet revenue days operating in the spot market in the fourth quarter have been fixed at an average rate of approximately $6,800 per day. In the Product Fleet, 59% of revenue days operating in the spot market have been fixed at an average rate of approximately $9,000 per day in the fourth quarter of 2020. The Product Fleet includes a weighted average blend of MR2 vessels, fixed on 60% of revenue days at an average rate of $9,400 per day, and MR1 vessels, fixed on 53% of fourth quarter revenue days at an average rate of $6,000 per day.

Conference Call

The Company will hold a conference call on November 16, 2020 at 8:00 a.m. Eastern Time to discuss its results for the third quarter of 2020.

To access the call, participants should dial +1 866 211-4137 for domestic callers and +1 647 689-6723 for international callers. Participants are encouraged to dial in ten minutes prior to the call. Please enter passcode 6646328.

A live webcast of the conference call will be available from the Company’s website at www.diamondsshipping.com.

An audio replay of the conference call will be available starting at 11 a.m. ET on Monday November 16, 2020 through Monday, November 23, 2020 by dialing in +1 800 585-8367 or +1 416 621-4642 and entering the passcode 6646328.

About Diamond S Shipping Inc.

Diamond S Shipping Inc. (NYSE: DSSI) owns and operates 66 vessels on the water, including 15 Suezmax vessels, one Aframax and 50 medium-range (MR) product tankers. Diamond S is one of the largest energy shipping companies providing seaborne transportation of crude oil, refined petroleum and other petroleum products. The Company is headquartered in Greenwich, CT. More information about Diamond S can be found at www.diamondsshipping.com.

Disclosure Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward‐looking statements including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Although management believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, there can be no assurance that the Company will achieve or accomplish these expectations, beliefs or projections. Some of the factors that could cause our actual results or conditions to differ materially include unforeseen liabilities; future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the Company’s operations; risks relating to the integration of assets or operations of entities that it has or may in the future acquire and the possibility that the anticipated synergies and other benefits of such acquisitions may not be realized within expected timeframes or at all; the failure of counterparties to fully perform their contracts with the Company; the strength of world economies and currencies; the duration and impact of the COVID-19 (coronavirus) outbreak; general market conditions, including fluctuations in charter rates and vessel values; changes in demand for tanker vessel capacity; changes in the Company’s operating expenses, including bunker prices; drydocking and insurance costs; the market for the Company’s vessels; availability of financing and refinancing; charter counterparty performance; ability to obtain financing and comply with covenants in such financing arrangements; changes in governmental rules and regulations or actions taken by regulatory authorities; potential liability from pending or future litigation; general domestic and international political conditions; potential disruption of shipping routes due to accidents or political events; vessels breakdowns and instances of off‐hires; and other factors. Please see the Company’s filings with the SEC for a more complete discussion of certain of these and other risks and uncertainties. The Company undertakes no obligation, and specifically declines any obligation, except as required by law, to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise.

 

DIAMOND S SHIPPING INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

as of September 30, 2020 and December 31, 2019

(In Thousands, except for share and per share data)

(Unaudited)

 

 

September 30,

2020

December 31,

2019

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$

114,335

 

$

83,609

 

Due from charterers – Net of provision for doubtful accounts of $2,037 and $1,415, respectively

 

56,948

 

 

80,691

 

Inventories

 

20,518

 

 

32,071

 

Prepaid expenses and other current assets

 

14,611

 

 

13,179

 

Total current assets

 

206,412

 

 

209,550

 

 

 

 

Noncurrent assets:

 

 

Vessels – Net of accumulated depreciation of $631,438 and $553,483, respectively

 

1,799,835

 

 

1,865,738

 

Other property – Net of accumulated depreciation of $813 and $584, respectively

 

433

 

 

642

 

Deferred drydocking costs – Net of accumulated amortization of $24,406 and $17,975, respectively

 

34,016

 

 

37,256

 

Restricted cash

 

6,014

 

 

5,610

 

Advances to Norient pool

 

8,001

 

 

 

Time charter contracts acquired – Net of accumulated amortization of $4,290 and $2,296, respectively

 

2,809

 

 

5,004

 

Other noncurrent assets

 

2,593

 

 

4,582

 

Total noncurrent assets

 

1,853,701

 

 

1,918,832

 

Total

$

2,060,113

 

$

2,128,382

 

 

 

 

Liabilities and Equity

 

 

Current liabilities:

 

 

Current portion of long-term debt

$

134,389

 

$

134,389

 

Accounts payable and accrued expenses

 

35,336

 

 

44,062

 

Deferred charter hire revenue

 

3,245

 

 

1,934

 

Derivative liability

 

557

 

 

 

Total current liabilities

 

173,527

 

 

180,385

 

 

 

 

Long-term debt – Net of deferred financing costs of $13,426 and $15,866, respectively

 

600,703

 

 

744,055

 

Derivative liability

 

620

 

 

 

Total liabilities

 

774,850

 

 

924,440

 

 

 

 

 

 

 

Equity:

 

 

Common stock, par value $0.001; 100,000,000 shares authorized; issued and outstanding 39,924,892 and 39,890,699 shares at September 30, 2020 and December 31, 2019, respectively

 

40

 

 

40

 

Treasury stock – at cost; 137,289 shares at September 30, 2020

 

(1,418

)

 

 

Additional paid-in capital

 

1,240,521

 

 

1,237,658

 

Accumulated other comprehensive loss

 

(1,177

)

 

 

Retained earnings (accumulated deficit)

 

12,525

 

 

(68,567

)

Total Diamond S Shipping Inc. equity

 

1,250,491

 

 

1,169,131

 

Noncontrolling interests

 

34,772

 

 

34,811

 

Total equity

 

1,285,263

 

 

1,203,942

 

Total

$

2,060,113

 

$

2,128,382

 

DIAMOND S SHIPPING INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

for the Three and Nine Months Ended September 30, 2020 and 2019

(In Thousands, except for share and per share data)

(Unaudited)

 

 

For the Three Months Ended

September 30,

 

For the Nine Months Ended

September 30,

 

 

2020

 

 

 

2019

 

 

 

2020

 

 

 

2019

 

Revenue:

 

 

 

 

Voyage revenue

$

69,098

 

$

120,954

 

$

419,169

 

$

348,747

 

Time charter revenue

 

20,408

 

 

20,572

 

 

63,296

 

 

44,730

 

Pool revenue

 

23,091

 

 

 

 

23,410

 

 

 

Total revenue

 

112,597

 

 

141,526

 

 

505,875

 

 

393,477

 

 

 

 

 

 

Operating expenses:

 

 

 

 

Voyage expenses

 

32,896

 

 

59,968

 

 

156,926

 

 

167,441

 

Vessel expenses

 

44,758

 

 

41,799

 

 

128,032

 

 

108,976

 

Depreciation and amortization expense

 

29,067

 

 

28,763

 

 

86,598

 

 

79,962

 

Loss on sale of vessels

 

 

 

18,344

 

 

 

 

18,344

 

General and administrative expenses

 

7,685

 

 

7,566

 

 

23,294

 

 

21,174

 

Total operating expenses

 

114,406

 

 

156,440

 

 

394,850

 

 

395,897

 

Operating income

 

(1,809

)

 

(14,914

)

 

111,025

 

 

(2,420

)

Other (expense) income:

 

 

 

 

Interest expense

 

(7,019

)

 

(13,021

)

 

(28,106

)

 

(35,813

)

Other income

 

3

 

 

492

 

 

339

 

 

1,393

 

Total other expense – Net

 

(7,016

)

 

(12,529

)

 

(27,767

)

 

(34,420

)

Net (loss) income

 

(8,825

)

 

(27,443

)

 

83,258

 

 

(36,840

)

Less: Net income (loss) attributable to noncontrolling interest (1)

 

839

 

 

(1,548

)

 

2,166

 

 

(1,416

)

Net (loss) income attributable to Diamond S Shipping Inc.

$

(9,664

)

$

(25,895

)

$

81,092

 

$

(35,424

)

 

 

 

 

 

Net (loss) earnings per share – basic

$

(0.24

)

$

(0.65

)

$

2.03

 

$

(0.99

)

Net (loss) earnings per share – diluted

$

(0.24

)

$

(0.65

)

$

2.02

 

$

(0.99

)

 

 

 

 

 

Weighted average common shares outstanding – basic

 

39,918,427

 

 

39,890,698

 

 

39,879,976

 

 

35,835,477

 

Weighted average common shares outstanding – diluted

 

39,918,427

 

 

39,890,698

 

 

40,106,157

 

 

35,835,477

 

(1)

The Company is a 51% owner in NT Suez Holdco LLC (“NT Suez”), a joint venture that owns two Suezmax vessels. The Company also performs commercial, technical and administrative services for this joint venture.

DIAMOND S SHIPPING INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

for the Nine Months Ended September 30, 2020 and 2019

(In Thousands)

(Unaudited)

 

 

For the Nine Months Ended

September 30,

 

 

2020

 

 

 

2019

 

Cash flows from Operating Activities:

 

 

Net income (loss)

$

83,258

 

$

(36,840

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

Depreciation and amortization expense

 

86,598

 

 

79,962

 

Loss on sale of vessels

 

 

 

18,344

 

Amortization of deferred financing costs

 

2,663

 

 

3,106

 

Amortization of time charter hire contracts acquired

 

2,194

 

 

1,632

 

Amortization of the realized gain from recouponing swaps

 

 

 

(2,045

)

Stock-based compensation expense

 

3,607

 

 

2,162

 

Changes in assets and liabilities

 

20,692

 

 

(11,723

)

Payments for drydocking

 

(5,120

)

 

(12,685

)

Net cash provided by operating activities

 

193,892

 

 

41,913

 

 

 

 

Cash flows from Investing Activities:

 

 

Acquisition costs, net of cash acquired of $16,568

 

 

 

(292,683

)

Transaction costs

 

 

 

(18,930

)

Proceeds from sale of vessels

 

 

 

31,800

 

Payments for vessel additions and other property

 

(11,958

)

 

(11,238

)

Net cash used in investing activities

 

(11,958

)

 

(291,051

)

 

 

 

Cash flows from Financing Activities:

 

 

Borrowings on long-term debt

 

 

 

300,000

 

Principal payments on long-term debt

 

(100,792

)

 

(86,604

)

Borrowings on revolving credit facilities

 

 

 

61,000

 

Repayments on revolving credit facilities

 

(45,000

)

 

(26,323

)

NT Suez Holdco LLC distribution

 

(2,205

)

 

 

Shares repurchased

 

(1,418

)

 

 

Cash paid to net settle employee withholding taxes on equity awards

 

(745

)

 

 

Proceeds from partners’ contributions in subsidiaries

 

 

 

980

 

Payments for deferred financing costs

 

(644

)

 

(6,970

)

Net cash (used in) provided by financing activities

 

(150,804

)

 

242,083

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

31,130

 

 

(7,055

)

Cash, cash equivalents and restricted cash – Beginning of period

 

89,219

 

 

88,158

 

Cash, cash equivalents and restricted cash – End of period

$

120,349

 

$

81,103

 

 

 

 

Supplemental disclosures:

 

 

Cash paid for interest

$

26,480

 

$

35,206

 

Common stock issued to CPLP

$

 

$

236,848

 

Unpaid transaction costs in Accounts payable and accrued expenses at the end of the period

$

 

$

154

 

Unpaid vessel additions in Accounts payable and accrued expenses at the end of the period

$

1,326

 

$

4,604

 

DIAMOND S SHIPPING INC. AND SUBSIDIARIES

Crude & Product Operating Data

(Unaudited)

 

For the Three Months Ended

September 30,

 

For the Nine Months Ended

September 30,

2020

 

2019

 

2020

 

2019

Crude

Fleet

 

Product

Fleet
(A)

 

Crude

Fleet

 

Product

Fleet
(A)

 

Crude

Fleet

 

Product

Fleet
(A)

 

Crude

Fleet

 

Product

Fleet
(A)

Time Charter TCE per day(1)

$26,073

$14,407

$26,134

$14,409

$26,277

$14,369

$26,127

$14,510

Spot TCE per day(1),(2)

20,224

10,374

18,174

12,714

37,120

15,176

17,966

13,356

Total TCE per day(1),(2)

$21,386

$11,113

$18,938

$13,139

$34,988

$15,016

$18,439

$13,610

Vessel operating expenses per day(3)

$7,995

$7,191

$7,139

$6,503

$7,578

$6,755

$6,889

$6,537

Revenue days(4)

1,389

4,539

1,337

4,445

4,175

13,476

3,854

11,706

Operating days(4)

1,472

4,600

1,472

4,751

4,384

13,700

4,024

12,719

 

(A) Product Fleet Operating Data

For the Three Months Ended

September 30,

 

For the Nine Months Ended

September 30,

2020

 

2019

 

2020

 

2019

MR

Fleet

 

Handy

Fleet

 

MR

Fleet

 

Handy

Fleet

 

MR

Fleet

 

Handy

Fleet

 

MR

Fleet

 

Handy

Fleet

Time Charter TCE per day(1)

$14,372

$14,686

$15,149

$12,164

$14,612

$13,073

$15,137

$12,231

Spot TCE per day(1),(2)

11,023

5,797

12,943

9,947

15,626

11,639

13,508

10,941

Total TCE per day(1),(2)

$11,643

$7,279

$13,415

$11,100

$15,433

$12,009

$13,818

$11,595

Vessel operating expenses per day(3)

$7,174

$7,317

$6,502

$6,935

$6,728

$6,954

$6,517

$7,155

Revenue days(4)

3,987

552

3,915

530

11,836

1,640

10,610

1,095

Operating days(4)

4,048

552

4,199

552

12,056

1,644

11,597

1,122

 

(1)

Time charter equivalent (“TCE”) revenue represents voyage revenues, which commence at the time a vessel departs its last discharge port and end at the time the discharge of cargo at the next discharge port is complete, less voyage expenses incurred over such time. TCE rates are a non-GAAP measure, generally used in the shipping industry, used to compare revenue generated from voyage charters to revenue generated from time charters. TCE rates assist the Company’s management in making decisions regarding the deployment and use of its vessels and in evaluating the financial performance of vessels under commercial management. See Non-GAAP Measures below.

(2)

Revenues are derived on a discharge-to-discharge basis less voyage expenses which primarily consist of fuel costs and port charges incurred over the same period. Voyage revenues, as presented in the income statement, are reported under a load-to-discharge basis under U.S. GAAP. A reconciliation is provided in the Non-GAAP Measures section of the press release.

(3)

The vessel operating expenses primarily consist of crew wages and associated costs, insurance premiums, lubricants and spare parts, technical management fees and repair and maintenance costs and excludes nonrecurring items.

(4)

Operating days include the calendar days in the period of owned vessels. Revenue days represent operating days less technical off-hire and drydocking.

Non-GAAP Measures

To supplement the Company’s financial information presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”), management uses certain “non-GAAP financial measures” as such term is defined in Regulation G promulgated by the Securities and Exchange Commission (the “SEC”). Generally, a non-GAAP financial measure is a numerical measure of a company’s operating performance, financial position or cash flows that excludes or includes amounts that are included in, or excluded from, the most directly comparable measure calculated and presented in accordance with GAAP. Management believes the presentation of these measures provides investors with greater transparency and supplemental data relating to the Company’s financial condition and results of operations, and therefore a more complete understanding of factors affecting its business than GAAP measures alone.

TCE revenue, TCE per day, earnings before interest, taxes, depreciation and amortization (“EBITDA”), and EBITDA adjusted for the impact of certain items that we do not consider indicative of our ongoing operating performance (“Adjusted EBITDA”) are non-GAAP financial measures that are presented in this press release and that the Company believes provide investors with a means of evaluating and understanding how the Company’s management evaluates the Company’s operating performance. These non-GAAP financial measures should not be considered in isolation from, as substitutes for, nor superior to financial measures prepared in accordance with GAAP. Please see below for reconciliations of TCE revenue, TCE per day, EBITDA and Adjusted EBITDA.

Reconciliation of Voyage Revenue to TCE per Day

(in thousands of U.S. dollars, except fleet data)

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

2020

 

2019

 

2020

 

2019

Crude

Fleet

 

Product

Fleet

 

Crude

Fleet

 

Product

Fleet

 

Crude

Fleet

 

Product

Fleet

 

Crude

Fleet

 

Product

Fleet

 

 

 

 

 

 

 

 

 

 

 

 

Voyage revenue

$42,293

$70,304

$46,222

$95,304

$202,795

$303,080

$133,105

$260,372

Voyage expense

(12,891)

(20,005)

(22,919)

(37,049)

(55,900)

(101,026)

(64,383)

(103,058)

Amortization of time charter contracts acquired

581

96

581

179

1,743

452

1,181

449

Off-hire bunkers in voyage expenses

212

33

408

622

493

334

619

1,278

Commercial management pool fees

1,024

 

 

1,033

 

Load-to-discharge/Discharge-to-discharge

(492)

(1,014)

1,037

(648)

(3,054)

(1,509)

536

295

Revenue from sold vessels

1

(5)

(10)

(25)

TCE Revenue

$29,703

$50,439

$25,329

$58,403

$146,077

$202,354

$71,058

$159,310

Operating days

1,472

4,600

1,472

4,751

4,384

13,700

4,024

12,719

Off-hire/Dry Docking days

83

61

135

306

209

224

170

1,014

Revenue days

1,389

4,539

1,337

4,445

4,175

13,476

3,854

11,706

TCE per day

$21,386

$11,113

$18,938

$13,139

$34,988

$15,016

$18,439

$13,610

Reconciliation of Net Income/(Loss) to EBITDA and Adjusted EBITDA

EBITDA represents net income (loss) before interest expense, income taxes and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted for the impact of certain items that we do not consider indicative of our ongoing operating performance. EBITDA and Adjusted EBITDA are presented to provide investors with meaningful additional information that management uses to monitor ongoing operating results and evaluate trends over comparative periods. EBITDA and Adjusted EBITDA do not represent, and should not be considered a substitute for, net income (loss) or cash flows from operations determined in accordance with GAAP. EBITDA and Adjusted EBITDA have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of our results reported under GAAP. Some limitations are:

  • EBITDA and Adjusted EBITDA do not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments;
  • EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs; and
  • EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debt.

While EBITDA and Adjusted EBITDA are frequently used by companies as a measure of operating results and performance, neither of those items as prepared by the Company is necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. The following table reconciles net income/(loss), as reflected in the consolidated statements of operations, to EBITDA and Adjusted EBITDA:

(in thousands of U.S. dollars)

For the Three Months

Ended September 30,

 

For the Nine Months

Ended September 30,

2020

 

2019

 

2020

 

2019

 

 

 

 

 

 

 

 

Net income (loss)

$(8,825)

$(27,443)

$83,258

$(36,840)

Total other expense, net

7,016

12,529

27,767

34,420

Operating income

(1,809)

(14,914)

111,025

(2,420)

Depreciation and amortization

29,067

28,763

86,598

79,962

Noncontrolling interest

(1,644)

631

(4,781)

(1,395)

EBITDA

$25,614

$14,480

$192,842

$76,147

Fair value of TC amortization

676

 

760

 

2,194

 

1,632

Nonrecurring corporate expenses

846

 

387

 

846

 

2,057

Gain/Loss on Sale of Assets

 

18,344

 

 

18,344

Adjusted EBITDA

$27,136

$33,971

$195,882

$98,180

 

Investor Relations Inquiries:

Robert Brinberg

Tel: +1-212-517-0810

E-mail: [email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Maritime Energy Transport Oil/Gas

MEDIA:

Logo
Logo

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option to Help Address the HIV Epidemic with Focus on Women in Sub-Saharan Africa

KENILWORTH, N.J.–(BUSINESS WIRE)–
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP)1 option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa. The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir — Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and prevention — and is anticipated to begin by early 2021. More than half of new HIV infections globally occur in sub-Saharan Africa, with women accounting for nearly 60 percent of new infections in this region.

“Our collaboration with the Bill & Melinda Gates Foundation exemplifies our shared mission to end the global HIV epidemic through meaningful innovations in HIV prevention, including additional PrEP options,” said Dr. Roy D. Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. Through this collaboration, we can further explore the potential of islatravir as part of our work towards the collective global public health goal of reducing the number of new HIV infections.”

“The world will not be able to end the HIV epidemic until we can effectively prevent HIV acquisition in at-risk individuals and populations,” said Dr. Emilio Emini, director of the TB & HIV program, the Bill & Melinda Gates Foundation. “This collaboration will help advance HIV science and potentially offer a new option to prevent HIV acquisition among at-risk women, both in sub-Saharan Africa and globally.”

Per the agreement between the foundation and Merck, the foundation, in its role as a funder, intends to provide grant funding to the International Clinical Research Center (ICRC) at the University of Washington Department of Global Health, which is collaborating with Merck on the IMPOWER 22 study. This grant will support ICRC’s work with experienced trial sites in sub-Saharan Africa to enroll, follow and retain the large number of women required for this research. Merck will be the trial sponsor, responsible for supplying the medicine, gaining regulatory and customs approvals, and providing operational expertise and resources for management of the trial, such as site monitoring and data reporting. Merck will be funding the IMPOWER 22 clinical trial in the United States.

“Globally, women continue to be underserved in HIV research and care. In 2019, women accounted for 48 percent of new infections, and in 2018, AIDS-related illnesses remained the leading cause of death for women during their reproductive years,” said Prof. Elizabeth Anne Bukusi, MBChB, PhD, senior principal clinical research scientist and co-director of the Research Care Training Program at the Center for Microbiology Research of The Kenya Medical Research Institute, and a trial investigator. “We will not turn the tide on HIV globally until we turn the tide on the virus in Africa, and this clinical trial seeks to help advance this effort through its focus on women, especially younger women, who remain disproportionately at risk on this continent.”

About IMPOWER Clinical Trials Program

IMPOWER 22is a randomized, active-controlled, double-blind, multisite Phase 3 study evaluating the efficacy and safety of islatravir administered orally once-monthly as PrEP in cisgender women who are at high risk for HIV-1 infection in sub-Saharan Africa and the United States. The active comparator for this study, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), will be administered orally once daily. Approximately 4,500 cisgender women and adolescent girls, ages 16 through 45, will be randomized (stratified by site and age) in a 1:1 ratio to receive either islatravir or FTC/TDF for the duration of the study. Information on this study will be posted shortly on www.clinicaltrials.gov.

Merck also plans to conduct additional studies in HIV prevention with islatravir in once-monthly oral PrEP. These studies will include IMPOWER 24, a global Phase 3 clinical trial to evaluate islatravir as a once-monthly oral agent for PrEP at sites across the world and among other key populations impacted by the epidemic, including men who have sex with men (MSM) and transgender women.

About Islatravir (MK-8591)

Islatravir (formerly MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently being evaluated in clinical trials for the treatment of HIV-1 infection in combination with other antiretrovirals, as well as for pre-exposure prophylaxis (PrEP) of HIV-1 infection as a single investigational agent, across a variety of formulations. In 2012, Merck licensed islatravir (4’-ethynyl-2-fluoro-2’-deoxyadenosine or EFdA) from the Yamasa Corporation based in Choshi, Japan.

Merck’s Commitment to HIV

For more than 30 years, Merck has been committed to scientific research and discovery in HIV, and we continue to be driven by the conviction that more medical advances are still to come. Our focus is on pursuing research that addresses unmet medical needs and helps people living with HIV and their communities. We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges that hinder continued progress.

About the Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill and Melinda Gates and Warren Buffett.

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

1 PrEP is a way for people who do not have HIV, who are considered high-risk for acquiring HIV, to prevent the infection. Currently, the only available/approved dosing option is to take a pill every day. PrEP has been shown to effectively reduce the risk of HIV infection from sex when taken daily, but is less effective if it is not taken consistently. (Source: https://www.cdc.gov/hiv/risk/prep/index.html)

Media:

Pamela Eisele

(267) 305-3558

Sarra S. Herzog

(201) 669-6570

Investors:

Peter Dannenbaum

(908) 740-1037

Michael DeCarbo

(908) 740-1807

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Biotechnology AIDS Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo

Iterum Therapeutics Reports Third Quarter 2020 Financial Results

NDA Filing Expected Q4 2020

DUBLIN, Ireland and CHICAGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2020.

“Following the positive feedback we received from the FDA at our pre-NDA meeting in September, we have been diligently preparing our new drug application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs) due to quinolone-resistant pathogens for submission in the coming weeks, and are making preparations for a potential commercial launch of oral sulopenem in the U.S.,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “With potential approval anticipated within the next three quarters, we are pleased to be the first oral penem to market in the U.S., and the first approved product in uUTI in over 20 years, where quinolone-resistant pathogens now cause as many as one third of the 22 million uUTIs annually.”

Q3 2020 Highlights and Recent Events

  • Positive meeting with the FDA resulting in continued preparation for submission of the NDA filing in the near-term:  Based on discussions with the FDA at a pre-NDA meeting in September 2020 and previous correspondence with the FDA, the Company plans to proceed with an NDA submission for oral sulopenem (sulopenem etzadroxil/probenecid) for the treatment of uUTIs in patients with a quinolone non-susceptible pathogen in the fourth quarter of 2020. In June 2020, as previously disclosed, the Company announced topline data from the SURE-1 clinical trial demonstrating that oral sulopenem was statistically superior to ciprofloxacin in the treatment of patients with uUTI caused by a quinolone non-susceptible pathogen.
  • Extended cash runway: In October 2020, the Company raised approximately $17.4 million gross proceeds (approximately $15.3 million net proceeds) in a registered public offering of ordinary shares, pre-funded warrants exercisable for ordinary shares and warrants exercisable for ordinary shares, which extended the Company’s expected cash runway into the third quarter of 2021.
  • Presented results from two Phase 3 studies at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 (IDWeek): In October 2020, the Company presented results from two of its Phase 3 clinical trials at IDWeek. The two data presentations included a poster presentation of the results of the SURE-2 clinical trial in complicated urinary tract infections, and an oral abstract presentation of the results from the SURE-1 clinical trial in uUTIs.

Third Quarter 2020 Financial Results

As of September 30, 2020, the Company had cash and cash equivalents of $8.6 million and approximately 21.2 million shares outstanding. In October 2020, the Company issued and sold, in a public offering, ordinary shares, pre-funded warrants exercisable for ordinary shares and warrants exercisable for ordinary shares for aggregate gross proceeds of approximately $17.4 million and net proceeds of approximately $15.3 million after deducting fees payable to the placement agent and other estimated offering expenses. The Company expects that its current cash and cash equivalents, including the proceeds from the October 2020 financing, will be sufficient to fund its operations into the third quarter of 2021. The Company is continuing to evaluate its corporate, organizational, strategic, financial and financing alternatives with the goal of maximizing value for its stakeholders, while prudently managing its resources.

Research and development (R&D) expenses for the third quarter of 2020 were $3.9 million compared to $28.1 million for the same period in 2019. The decrease was primarily due to reduced clinical trial expenses and headcount associated with the completion of the Company’s Phase 3 clinical trials, which had been initiated in the third quarter of 2018.

General and administrative (G&A) expenses for the third quarter of 2020 were $2.4 million compared to $2.9 million in the same period in 2019. The decrease was primarily due to a decrease in headcount and related costs, lower spending on pre-commercialization activities and reduced share-based compensation to directors, partially offset by an increase in share-based compensation for employees in our general and administrative functions.

Interest expense, net in the third quarter of 2020 was $4.2 million compared to $0.2 million in the same period in 2019, primarily due to non-cash interest expense and amortization of debt discounts and deferred financing costs relating to the Company’s Exchangeable Notes and Royalty-Linked Notes issued in 2020.

For the third quarter of 2020, the Company reported a net loss of $12.2 million compared to a net loss of $31.3 million for the same period in 2019.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Company’s plans, strategies and prospects for its business, including with respect to the Company’s planned filing and FDA review of an NDA for oral sulopenem and the sufficiency of the Company’s cash resources. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company’s control, including the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of the Company’s expectations regarding how far into the future the Company’s cash on hand will fund the Company’s ongoing operations, the Company’s ability to continue as a going concern, the impact of COVID-19 and related responsive measures thereto, the Company’s ability to maintain its listing on the Nasdaq Stock Market, risks and uncertainties concerning the outcome, impact, effects and results of the Company’s evaluation of corporate, organizational, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, organizational, strategic, financial or financing alternative and the Company’s ability to complete one at all, the price of the Company’s securities and other factors discussed under the caption “Risk Factors” in its most recently filed Quarterly Report on Form 10-Q, and other documents filed with the Securities and Exchange Commission from time to time. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Investor Contact:

Judy Matthews
Chief Financial Officer
312-778-6073
[email protected]

 
ITERUM THERAPEUTICS PLC
Condensed Consolidated Statement of Operations
(In thousands except share and per share data)
(Unaudited)
                 
    Three months ended
September 30,
  Nine months ended
September 30,
    2020   2019   2020   2019
Revenue   $     $     $     $ 37  
Operating expenses:                
Research and development     (3,937 )     (28,066 )     (18,723 )     (69,892 )
General and administrative     (2,398 )     (2,933 )     (8,759 )     (8,988 )
Total operating expenses     (6,335 )     (30,999 )     (27,482 )     (78,880 )
Operating loss     (6,335 )     (30,999 )     (27,482 )     (78,843 )
Interest expense, net     (4,183 )     (216 )     (10,854 )     (455 )
Financing transaction costs     (685 )           (2,815 )      
Adjustments to fair value of derivatives     (644 )           1,023        
Other income, net     68       48       27       204  
Income tax expense     (420 )     (104 )     (719 )     (395 )
Net loss attributable to ordinary shareholders   $ (12,199 )   $ (31,271 )   $ (40,820 )   $ (79,489 )
Net loss per share attributable to ordinary shareholders – basic and diluted   $ (0.60 )   $ (2.15 )   $ (2.39 )   $ (5.52 )
Weighted average ordinary shares outstanding – basic and diluted     20,392,357       14,571,278       17,078,326       14,412,755  
                 
Net loss – GAAP   $ (12,199 )   $ (31,271 )   $ (40,820 )   $ (79,489 )
Interest expense – accrued interest and amortization on Exchangeable Notes and Royalty-Linked Notes     3,859             9,829        
Financing transaction costs – not capitalized     685             2,815        
Adjustments to fair value of derivatives     644             (1,023 )      
Non-GAAP adjusted loss   $ (7,011 )   $ (31,271 )   $ (29,199 )   $ (79,489 )
Net loss per share attributable to ordinary shareholders – basic and diluted   $ (0.60 )   $ (2.15 )   $ (2.39 )   $ (5.52 )
Non-GAAP net loss per share attributable to ordinary shareholders – basic and diluted   $ (0.34 )   $ (2.15 )   $ (1.71 )   $ (5.52 )
                 
                 
ITERUM THERAPEUTICS PLC        
Condensed Consolidated Balance Sheet Data        
(In thousands)        
(Unaudited)        
                 
    As of   As of        
    September 30,   December 31,        
    2020   2019        
Cash and cash equivalents   $ 8,570     $ 4,801          
Other assets     17,700       20,950          
Total assets   $ 26,270     $ 25,751          
Long-term debt, less current portion   $ 21,653     $ 7,625          
Royalty-linked notes, less current portion     12,492                
Derivative liabilities     26,097                
Other liabilities     21,931       44,364          
Total liabilities     82,173       51,989          
Total shareholders’ deficit     (55,903 )     (26,238 )        
Total liabilities and shareholders’ deficit   $ 26,270     $ 25,751          
                 



Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Adamis’ ZIMHI™ high dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission.

A CRL is issued by the FDA’s Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form.  The questions raised by the FDA related generally to new Chemistry, Manufacturing and Controls (CMC) issues. It should be noted that no issues related to “extractables and leechables testing”, that were associated with the previous initial CRL that the company received relating to the product, were noted by the FDA. The company’s plan is to provide the FDA with additional analysis and information in order to attempt to satisfy the CRL items. The company will request a Type A meeting or consider other options to resolve the issues.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “This is a very disappointing setback that was totally unexpected since we completed the extractables and leechables issues that were associated with the first CRL. To me, it is very surprising to have new issues brought up this late in the review process. We believe the comments and recommendations stated in the CRL can be addressed and overcome. With all of the factors that are currently contributing to a growing number of fatal overdoses during the COVID-19 pandemic, we believe there is a clear need for higher dose forms of intramuscular naloxone found in ZIMHI. We remain committed to this product and our mission to provide physicians and patients access to a higher dose of naloxone. As soon as reasonably possible, we will resubmit additional information and analysis of data to the FDA for the NDA.”

About ZIMHI

ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose. Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. According to statistics published by the Centers for Disease Control and Prevention (CDC) in 2018, drug overdoses resulted in approximately 67,000 deaths in the United States – greater than 185 deaths per day.  Drug overdoses are now the leading cause of death for Americans under 50, and more powerful synthetic opioids, like fentanyl and its analogues, are responsible for the largest number of deaths from opioid overdoses.

About
Adamis
Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  In addition to its ZIMHI, naloxone injection product candidate, Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning its ability to satisfactorily respond to the matters raised in the FDA’s CRL; the company’s beliefs concerning the information, data and actions that the FDA may require in connection with any resubmitted NDA relating to ZIMHI; the company’s beliefs concerning the results of any future studies or clinical trials that the company may conduct relating to ZIMHI or its other products or product candidates; the company’s beliefs concerning the timing and outcome of the FDA’s review of the company’s New Drug Application (NDA) relating to the ZIMHI product or any resubmitted NDA; the company’s beliefs concerning its ability to commercialize ZIMHI and its other products and product candidates; the company’s beliefs concerning the ability of its product candidates to compete successfully in the market; the company’s beliefs concerning the safety and effectiveness of ZIMHI or its other products and product candidates; the company’s beliefs concerning its commercialization strategies; and the company’s beliefs concerning the anticipated timing of any commercial launch of its ZIMHI product. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. The FDA may require additional studies, and/or other actions, data or information, prior to any resubmission of the NDA. There can be no assurances that the company will be able to satisfactorily respond to the matters raised in the FDA’s CRL or concerning the timing of any resubmission by us of the NDA responding to the CRL, concerning the timing or costs of any additional actions that may be required in connection with any resubmission of the NDA, that the FDA will approve any resubmitted NDA relating to our ZIMHI product or concerning the timing of any future action by the FDA on our NDA, or that the product will be able to compete successfully in the market if approved and launched. In addition, forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities.  As discussed in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if required.  You should not place undue reliance on any forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this press release speak only as the date of this press release, and Adamis expressly disclaims any obligation to update any forward-looking statements.

Contact Adamis:

Mark Flather
Senior Director, Investor Relations
& Corporate Communications
(858) 412-7951
[email protected]



Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare Conference

PR Newswire

OSLO, Norway, Nov. 16, 2020 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Jefferies Virtual London Healthcare Conference, taking place 17-19 November 2020.

Presentations details are as follows:

Jefferies Virtual London Healthcare Conference
Date: Thursday, 19 November 2020
Time: 2:40 to 3:10PM (GMT)

The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO


Cell: +44 7561 431 762

Email:

[email protected]
 

Media Enquiries


Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)



Tel: +44 203 926 8535

Email:

[email protected]
 

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-at-upcoming-jefferies-virtual-london-healthcare-conference,c3237807

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-at-upcoming-jefferies-virtual-london-healthcare-conference-301173509.html

SOURCE Nordic Nanovector

Resideo Announces Public Offering of Common Stock

PR Newswire

AUSTIN, Texas, Nov. 16, 2020/PRNewswire/ — Resideo Technologies, Inc. (NYSE:REZI) (“Resideo”) today announced that it has commenced an underwritten public offering of 17,000,000 shares of its common stock.

Resideo intends to use the net proceeds of this offering to repay borrowings under its revolving credit facility and for general corporate purposes, including funding growth investments and potential acquisitions.

Morgan Stanley and Evercore ISI are acting as lead joint book-running managers on the transaction. BofA Securities and J.P. Morgan are acting as additional bookrunners on the transaction. The underwriters will have the option to purchase up to an aggregate of 2,550,000 additional shares of common stock from Resideo.

The shares are being offered pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission (the “SEC”). This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, or solicitation to buy, if at all, will be made solely by means of a prospectus and related prospectus supplement filed with the SEC. You may obtain these documents without charge from the SEC at www.sec.gov.  Alternatively, you may request copies of these materials from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or from Evercore Group L.L.C, Attn: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by email at [email protected], or by telephone at (888) 474-0200.

About Resideo

Resideo is a global manufacturer and distributor of technology-driven products and solutions that provide comfort, security, energy efficiency and control to customers worldwide. Our ADI Global Distribution business is also a wholesale distributor of low-voltage security products with a global footprint serving commercial and residential end markets. Our primary focus is on the professional channel.

Forward-Looking Statements

This release contains “forward-looking statements,” including statements relating to the proposed offering and the anticipated use of the net proceeds from the offering.  All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results or performance of Resideo to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the completion of the offering on the anticipated terms or at all, market conditions, the satisfaction of customary closing conditions related to the offering, general economic, industry or political conditions, including the impact of the COVID-19 pandemic, and the other risks described under the headings “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” in our preliminary prospectus supplement filed November 16, 2020, our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended September 26, 2020 and other periodic filings we make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Except as required by law, we undertake no obligation to update such statements to reflect events or circumstances arising after the date of this press release, and we caution investors not to place undue reliance on any such forward-looking statements.


Contacts:


Investors:


Media:

Jason Willey

Oliver Clark


[email protected]


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/resideo-announces-public-offering-of-common-stock-301173504.html

SOURCE Resideo Technologies, Inc.

Walker & Dunlop Establishes Presence in Utah with New Hire in Salt Lake City

PR Newswire

BETHESDA, Md., Nov. 16, 2020 /PRNewswire/ — Walker & Dunlop, Inc. announced today that it has expanded its geographic footprint in the Western United States with the addition of Senior Director Colton Smith. Based in Salt Lake City, Utah, Mr. Smith will focus on sourcing debt financing for all commercial real estate asset classes nationally, as well as expanding the firm’s reach and capabilities within Salt Lake City and the greater Utah region.


Cliff Carnes
, Western Region Chief Production Officer for Walker & Dunlop, commented, “We are thrilled to welcome Colton to the team. As we continue to expand our platform throughout the United States, we consistently seek talent that reflects our commitment to superior client service. Colton has an excellent reputation and is very well-known in the industry. We have wanted a presence in Salt Lake City for several years, but knew we had to wait for the right talent. We have found that in Colton and are confident that his track record will accelerate our growth in Salt Lake City and the greater Utah area. This hire represents a significant opportunity for us to increase both our market share and client base.”

“I’m very pleased to join Walker & Dunlop, one of the most well-respected firms in the commercial real estate finance space,” said Smith. “In joining this platform, I have the opportunity to be a meaningful contributor to the company’s strategic growth and continue to provide best-in-class service to my clients.”

Mr. Smith brings over ten years of commercial real estate experience to Walker & Dunlop. Prior to joining Walker & Dunlop, Mr. Smith was a First Vice President with Marcus & Millichap, where he secured financing for multifamily, office, industrial, retail, seniors housing, and hospitality properties. Throughout his career, he has completed more than $1 billion in debt originations and has consistently been recognized as a top broker. Before Marcus & Millichap, Mr. Smith founded the commercial lending division for a Salt Lake City real estate conglomerate.

Walker & Dunlop is a leader in the commercial real estate finance industry, ranking as the top Fannie Mae DUS® multifamily lender, the 3rd largest Freddie Mac Optigo® multifamily lender by volume,  and the 3rd largest HUD lender based on MAP initial endorsements in 2019. The company has also achieved dramatic growth in its brokered loan origination volumes, which increased 23.4 percent from 2018 to 2019. This has largely been due to the company’s successful hiring and integration of talented bankers and brokers. Since the beginning of 2019, Walker & Dunlop has added 51 bankers and brokers to the platform.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 900+ professionals in 40 offices across the nation have an unyielding commitment to client satisfaction.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/walker–dunlop-establishes-presence-in-utah-with-new-hire-in-salt-lake-city-301173164.html

SOURCE Walker & Dunlop, Inc.